Unlock the power of data to fight Antimicrobial Resistance with Qiagen
Improve antibiotic prescription practices by predicting AMR & AMU with data triangulation
Time to effective antimicrobial therapy and avoidance of empiric treatment are essential to improve patient outcome and avoid emergence of in-therapy drug resistance. Improper therapy also leads to higher healthcare and societal costs.
In order to achieve optimization of care three sets of data could help if assessed together:
- Clinical data (prescription and clinical outcome)
- Microbiological diagnostic data (phenotypic)
- Molecular diagnostic data (genes, etc.)
Such data – if triangulated and analyzed accordingly – could lead to continuous surveillance of prevalent drivers of resistance, appropriateness and timeliness of drug prescription, evolution of resistance and ultimately lead to computerized clinical decision-support systems (CDSS). AI enabled algorithms would be required to build on the above-mentioned data and systems trained to predict resistance, anticipate antibiotic choice and alert system to risky practices with high chances of resistance emergence.
Current antibiotic prescription approaches rely on high levels of clinical suspicion for infection, severe infection and/or sepsis, and initiation of best available empiric treatment based on local guidelines. Escalation or de-escalation of therapy can only occur following results of diagnostic tests for which turnaround time (TOT) can be as long as 72 hrs. Within this period a high risk of adverse patient outcome and resistance emergence exist if the wrong antibiotic has been prescribed.
A system for predicting antimicrobial resistance is lacking due to poor utilization of molecular data for rapid antimicrobial choice as well as lack of analytical capacity to assess phenotypic results in relation to resistance marker findings and clinical outcomes.
- Antimicrobial stewardship program (ASP)
- Hospitals Pharmacy
- Hospital IT
- Central Lab & POC Managers
- Infectious disease physicians
Challenge owner
Qiagen
Disease area
Diagnostics and surveillance of antimicrobial resistance / Infectious diseases management and antimicrobial therapy
Registration deadline
23 April 2023
Status
Closed
What we are looking for:
Hospitals increasingly rely on computerized clinical decision-support systems (CDSS) to supply their antimicrobial stewardship program (ASP) teams with the relevant data & algorithms to ultimately identify patients who should be prioritized for review (surveillance) and provide suitable antimicrobial drugs treatment (AMR prediction).
The intended solutions could be the missing link to collating different type of data (clinical, phenotypic and molecular data) for triangulation.
The solution would need to seamlessly integrate with disparate testing sites throughout the hospital campus (Central & POC) and be compatible with different IT systems (EHR, LIMS) and diagnostics systems, including QIAGEN´s molecular diagnostics testing solutions such as QIAstat.Dx, NeuMoDX, QIAcuity, Quantiferon, CLC Genomics Workbench, and more. (check https://www.qiagen.com for more information)
The intended solution shall provide a system for predicting antimicrobial resistance by utilization of data (clinical, phenotypic and molecular data) and by means of purposely developed AI algorithms.
Furthermore, we would look for a data-driven web-based intelligent decision support tool that is UX-friendly and would assist antimicrobial stewardship (AMS) teams to automate daily routine tasks.
FAQ
Who can apply?
European incorporated companies with a product or technology that addresses the challenges released. At least, a prototype of the solution should exist. There are no further specific requirements in terms of Technology Readiness Level (TLR), sales, minimum investment attracted, or country of registration.
How can I apply to this challenge?
Click on „Apply now“ and follow the instructions to submit an application. You will answer different questions about your company and the product you present as a possible solution to the challenge.
How are applications evaluated?
The main selection criteria is product-challenge fit. Applications are sent to the relevant teams in each challenge-owner, who decide which companies are selected. To increase the chances of a successful application, make sure you carefully read the information we have published about each challenge and show in your application how your product could be a perfect match. The questions in the application will guide you!
Can I apply to more than one challenge?
Yes, of course! However, you will need to submit one individual application per challenge and customize it according to the challenge.
I have a solution for a challenge, but it still requires some changes or development. Can I still apply?
Yes, the main requirement is that your solution addresses the challenge. In case you are selected, during the meetings with the challenge owners, you can clarify the needs of both parties and decide on possible changes/modifications/extra features, etc.
We encourage you to apply even if your solution only fulfills some of the requirements of the „ideal solution“ described above. Both off-the-shelf and customizable options are relevant!
Where does Meet&Match.Dx take place?
Mostly online, with the possibility to organize meetings in person in the third module. If that happens, the travel and accommodation costs for the participants will be covered by a grant.
What is the cost for my company?
None, it is free of charge. No fee, no equity taken. You only need to bring professionalism and commitment to make the best out of this opportunity. The costs for services are covered by the EU-funded Interreg NWE Codex4SMEs project.
Is a collaboration 100% secured for the SMEs selected?
Neither party is obliged to enter into a partnership. We will create the optimal environment for a collaboration to start, but whether this happens, and the conditions of the collaboration, will be exclusively decided by the parties involved.
However, we guarantee 100% of the selected companies will be connected to the relevant teams within the challenge-owner, will have 1-on-1 partnership exploration meetings, and will receive support to prepare for that occasion in the best possible way.
My product or solution is not a fit for any of the challenges… what can I do?
We constantly release different challenges in collaboration with industry leaders and healthcare providers. Join our start-ups database and you will be immediately notified when new challenges are out!